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a b s t r a c t
During development a network of transcription factors functions to differentiate foregut cells into
pancreatic endocrine cells. Differentiation of appropriate numbers of each hormone-expressing endo-
crine cell type is essential for the normal development of the pancreas and ultimately for effective
maintenance of blood glucose levels. A fuller understanding of the details of endocrine cell differentia-
tion may contribute to development of cell replacement therapies to treat diabetes. In this study, by
using morpholino and gRNA/Cas9 mediated knockdown we establish that differential levels of the basic-
helix loop helix (bHLH) transcription factor Neurod are required for the differentiation of distinct
endocrine cell types in developing zebraﬁsh. While Neurod plays a role in the differentiation of all
endocrine cells, we ﬁnd that differentiation of glucagon-expressing alpha cells is disrupted by a minor
reduction in Neurod levels, whereas differentiation of insulin-expressing beta cells is less sensitive to
Neurod depletion. The endocrine cells that arise during embryonic stages to produce the primary islet,
and those that arise subsequently during larval stages from the intra-pancreatic duct (IPD) to ultimately
contribute to the secondary islets, show similar dependence on differential Neurod levels. Intriguingly,
Neurod-deﬁciency triggers premature formation of endocrine precursors from the IPD during early larval
stages. However, the Neurod-deﬁcient endocrine precursors fail to differentiate appropriately, and the
larvae are unable to maintain normal glucose levels. In summary, differential levels of Neurod are
required to generate endocrine pancreas subtypes from precursors during both embryonic and larval
stages, and Neurod function is in turn critical to endocrine function.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The hormone producing pancreatic endocrine cells of the islets
of Langerhans are crucial for proper regulation of blood glucose
levels. The islets comprise insulin-expressing beta cells, glucagon-
expressing alpha cells, somatostatin-expressing delta cells and
ghrelin-expressing epsilon cells. As beta cell loss or failure causes
diabetes, patients can potentially beneﬁt from cell replacement
therapies. Effective in vitro production of functional beta cells from
stem cells for use in replacement therapies will likely depend on a
fuller understanding of normal endocrine pancreas development.
However, our understanding of the precise mechanisms through
which multipotent endocrine progenitors differentiate into dis-
tinct endocrine cell types remains incomplete.
The vertebrate endocrine pancreas develops from dorsal
and ventral pancreatic buds, which form as out-pockets of the
endoderm-derived gut tube (Kinkel and Prince, 2009). In zebraﬁsh,
the dorsal bud gives rise to the initial primary endocrine islet, which is
already established at 24 h post fertilization (hpf), but complete
endocrine pancreas development requires the contribution of ventral
bud-derived cells. As the dorsal and ventral buds merge at around
52 hpf, endocrine cells from the ventral bud contribute to the primary
islet (Field et al., 2003). Subsequently, during larval stages, duct cells
provide a source of secondary endocrine cells that will ultimately
produce the secondary islets (Parsons et al., 2009). In both mammals
and zebraﬁsh the duct-derived secondary endocrine progenitors
are Notch responsive cells (NRCs) (Apelqvist et al., 1999; Jensen et al.,
2000; Kopinke et al., 2011; Ninov et al., 2012; Parsons et al., 2009).
Upon inhibition of Notch signaling, zebraﬁsh intra-pancreatic duct
(IPD)-NRCs precociously form secondary endocrine cells from as early
as 6 days post fertilization (dpf) (Ninov et al., 2012; Parsons et al., 2009;
Wang et al., 2011). While suppression of Notch signaling is sufﬁcient to
trigger endocrine cell production from the IPD, the molecular mechan-
isms guiding multipotent endocrine progenitor differentiation down-
stream of Notch suppression are not fully understood. In particular, it is
unclear whether initial development of the primary endocrine cells
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and subsequent development of secondary endocrine cells from the
IPD use equivalent mechanisms.
Endocrine pancreas cells in themouse develop from precursors that
transiently express the basic helix-loop-helix (bHLH) domain transcrip-
tion factor Neurog3 (Gu et al., 2002; Mellitzer et al., 2004; Schonhoff et
al., 2004), and Neurog3 mutant mice are unable to differentiate
endocrine pancreas cells (Gradwohl et al., 2000). By contrast, there is
no evidence that zebraﬁsh endocrine precursors express neurog3, or
other neurog homologs (Flasse et al., 2013), and neurog3 mutant
zebraﬁsh do not have any endocrine pancreas defects (Flasse et al.,
2013). Although Neurog transcription factors do not appear to play a
role in zebraﬁsh pancreas development, Flasse et al. (2013) did uncover
a role for the bHLH domain transcription factor Neurod; they showed
that simultaneous knockdown of Ascl1b and Neurod blocks zebraﬁsh
endocrine cell differentiation (Flasse et al., 2013). In mice, Neurog3
activates expression of NeuroD1 (Huang et al., 2000), and importantly,
NeuroD1 can substitute for Neurog3 in protocols to transform exocrine
cells to beta cells (Zhou et al., 2008). Mice lacking NeuroD1 fail to form
endocrine islets, develop diabetes and die shortly after birth (Naya et
al., 1997). Beta cell speciﬁc deletion of NeuroD1 leads to glucose
intolerance because the beta cells remain immature and fail to function
properly (Gu et al., 2010). In humans, homozygous mutations in
NEUROD1 are characterized by permanent neonatal diabetes (Rubio-
Cabezas et al., 2010). Together, these data suggest a conserved role for
Neurod homologs in endocrine pancreas development.
Here we have explored the role of zebraﬁsh Neurod in the
differentiation of endocrine pancreas cells. Analysis of specimens in
which gRNA/cas9 genome editing was used to generate predicted
null alleles has conﬁrmed that Neurod plays a critical function in
endocrine cell development. We have exploited a morpholino
knockdown strategy to investigate the consequences of differential
levels of Neurod knockdown, and report that different levels of
zebraﬁsh Neurod are required for the differentiation of particular
endocrine cell types. Speciﬁcally, alpha cell differentiation is depen-
dent on high levels of Neurod, while beta cell differentiation requires
lower levels. Using endoderm-speciﬁc gain of function we conﬁrm
that high levels of Neurod promote differentiation of glucagon-
expressing alpha cells. Although Neurod-deﬁcient larvae produce
precocious secondary endocrine precursors upon inhibition of Notch
signaling, these cells remain undifferentiated, indicating that larval
stage secondary endocrine cell differentiation is similarly dependent
on Neurod. Remarkably, Neurod-deﬁcient larvae initiate premature
endocrine cell differentiation from the IPD, suggesting the presence
of compensatory mechanisms to regulate endocrine cell numbers.
Consistent with the inability of Neurod-deﬁcient larvae to complete
the endocrine pancreas differentiation program to produce appro-
priate numbers of hormone-expressing cells, these specimens are
unable to maintain normal glucose levels.
Materials and methods
Zebraﬁsh husbandry
Zebraﬁsh (Danio rerio) were maintained as described (Westerﬁeld,
1995). Embryos were obtained from wild-type AB, TgBAC(neurod:
EGFP)nl1 [hereafter Tg(neurod:EGFP)] (Obholzer et al., 2008), Tg(mnx1:
GFP) (Dalgin et al., 2011), Tg(ptf1a:EGFP) (Godinho et al., 2005) and Tg
(-5.0sox17:EGFP)zf99 [hereafter Tg(sox17:EGFP)] (Mizoguchi et al.,
2008) lines, raised and staged as described (Kimmel et al., 1995).
Microinjections of morpholino antisense oligonucleotides
Morpholino (MO) antisense oligonucleotides for Neurod:
Neurod ATG MO: 50 TTTCCTCGCTGTATGACTTCGTCAT and Neu-
rod UTR MO: 50 TGACTTCGTCATGTCGGAACTCTAG (Sarrazin et al.,
2006) were purchased from Gene Tools, LLC. Mnx1 and Sox32 MOs
were used as described (Dalgin et al., 2011). Tg(neurod:EGFP)
embryos were microinjected at the one to two-cell stage with
1 nl of 1, 2 or 4 mg/ml Neurod ATG MO, or 2, 4 or 8 mg/ml Neurod
UTR MO. Due to overlap of the target sites in the UTR of neurod
and egfp transcripts Neurod UTR MOs were titrated away by the
transgene; therefore higher Neurod UTR MO concentrations were
used when injecting Tg(neurod:EGFP) embryos.
Whole mount in situ hybridization, immunohistochemistry, H2B-RFP
mRNA injections and imaging
Whole mount in situ hybridization and immunohistochemistry
were performed as described (Dalgin et al., 2011). The following
antibodies were used: polyclonal rabbit anti-active Caspase-3
(1:100; Millipore AB3623), rabbit anti-GFP488 (1:500; Molecular
Probes A21311), monoclonal mouse anti-glucagon (1:200; Sigma
G2654), polyclonal rabbit anti-phospho-Histone H3 (Ser10)
(1:100; Millipore 06-570), polyclonal guinea pig anti-insulin
(1:100; Dako A0564), Neurod antibody (1:100, GST fusion epitope
containing amino acids 1–57; a gift from Dr. Masahiko Hibi) (Kani
et al., 2010), polyclonal rabbit anti-somatostatin (1:200; MP
Biomedicals 11180). Plasmid to in vitro transcribe H2B-RFP mRNA
was kindly provided by Dr. Ryan M. Anderson. H2B-RFP mRNAwas
in vitro transcribed (Ambion MEGAscript SP6 kit-AM 1330) and
embryos were injected with 100 pg of capped synthetic mRNA at
the one-cell stage. To obtain ﬂuorescent images embryos were
ﬂat-mounted and imaged using a Zeiss LSM 710 confocal micro-
scope with 25 or 40 objectives. To obtain bright-ﬁeld images
embryos were deyolked, ﬂat-mounted, and photographed under a
Zeiss Axioskop microscope. Cell counting for bright-ﬁeld images
were performed under the microscope; to enable visualization of
single cells, chromogenic samples were monitored to avoid over-
staining. Cell counts for confocal images (merged z-stacks) were
performed using the Zeiss LSM 710 confocal microscope; z-stacks
of optical sections (2–4 mm) were taken for each specimen and
each stack was analyzed using the ImageJ cell counter plugin.
Real-time qPCR
Total RNAwas isolated from 20 embryos per group according to
manufacturer's instructions by removing genomic DNA contam-
ination (Qiagen 74104). cDNA was prepared using iScript cDNA
synthesis kit (Bio-Rad 170-8891). Primers were designed using
PrimerQuest system (IDT) (Table S1). cDNA was ampliﬁed using
StepOnePlus Real-Time PCR system (Applied Biosystems) with
Power SYBR Green PCR Master Mix (Applied Biosystems
4367659). Relative expression of each sample was determined
after normalization to beta-actin 1 (actb1) levels using the
efﬁciency-corrected delta Ct method (Bookout et al., 2006) and
displayed relative to an arbitrary value.
Cell transplantation
Transplantation was performed as described (Dalgin et al.,
2011; Ho and Kane, 1990; Stafford et al., 2006). Host embryos
were injected with 1 ng Sox32 MO at the one-cell stage. To achieve
Neurod knockdown in the endoderm, donor embryos were
injected at the one-cell stage with Neurod ATG MO (2 ng), together
with synthetic capped sox32 mRNA (100–200 pg; Ambion MEGA-
script SP6 kit-AM 1330) and 10 kDa ﬁxable rhodamine dextran
(RD: Molecular Probes). To achieve overexpression of neurod in
endoderm, donor embryos were injected at the one-cell stage with
neurod mRNA (100 pg; Ambion MEGAscript SP6 kit-AM 1330),
together with sox32 mRNA and 10 kDa ﬁxable RD. At 4 hpf 20–40
cells from a donor embryo were transplanted into the blastoderm
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margin of each host. Transplanted specimens with a fully recon-
stituted endoderm of normal morphology were assayed by whole-
mount immunohistochemistry at 52 hpf.
RO4929097, phlorizin treatments and glucose ﬂuorometric assay
RO4929097-gamma secretase inhibitor was purchased from Sell-
eckchem (S1575) and dissolved in DMSO. Three day old Tg(neurod:
EGFP) control or Neurod morphant embryos were incubated in
embryo medium (E3) containing 3 mM RO4929097 or DMSO carrier
(DMSO treated embryos were indistinguishable from untreated
controls; data not shown) until 6 dpf. Phloridzin (Phlorizin) dihy-
drate (Phz) was purchased from Sigma-Aldrich (P3449). Phz was
prepared fresh in E3 and ﬁltered (Fisher 09-719A, 0.22 mm) to
remove undissolved particles. Ten 5.5 dpf larvae were incubated in
a 12 well plate (Becton Dickson 353043) in E3 medium containing
250 mg/ml Phz for 16 h. We found that this treatment regimen was
optimal; treatments starting prior to this stage and for longer time
periods were toxic to larvae. Ten samples per group were frozen and
stored at 80 1C until analysis. For collections after 5 dpf, larvae
were fed (ZM Fish Food, ZM000) twice daily; on the day of collection
samples were harvested before the normal feeding time. Glucose
levels were determined using a colorimetric/ﬂuorometric assay kit
(Biovision, K606-100). A glucose standard curve was prepared
according to manufacturer's instructions. Samples were hand-
homogenized in PBS (20 ml/embryo). 20 ml of each sample was used
to assemble reactions, using 96-well black ﬂat bottom plates (Costar
3915) according to manufacturer's instructions. Fluorescence (Ex/
Em¼535/590) was measured using a Beckman Coulter DTX 880
Multimode microplate reader.
Microinjections of gRNA and Cas9 mRNA
The CHOPCHOP website (Montague et al., 2014) was used to
select genomic target sites on the zebraﬁsh neurod locus. We
designed an optimized single guide (sg) RNA scaffold, modiﬁed for
efﬁcient transcription and with an extended stem loop designed to




an SP6 promoter (underlined) and genomic target site (and Fig.
S12). This sequence was purchased as a gBlock from Integrated DNA
Technologies and used as a template for transcribing sgRNA. The
sgRNA was transcribed using the Ambion MEGAscript SP6 kit (AM
1330) with addition of 40U RNAsin (Promega N251A), and was
incubated at 37 1C for 90 min. RNA was then isolated according to
manufacturer's instructions with the addition of a phenol/chloroform/
isoamyl alcohol extraction and 20 mg of glycogen carrier (Thermo
Scientiﬁc R0551). Capped and polyadenylated 3xFLAG-NLS-SpCas9-
NLS (hereafter Cas9, Addgene 51307) mRNA (Guo et al., 2014) was also
transcribed using the Ambion MEGAscript SP6 kit (AM 1330). Tg
(neurod:EGFP) embryos were microinjected at the one-cell stage with
60 pg sgRNA and 500 pg Cas9 mRNA per embryo.
Isolation of genomic DNA, T7 endonuclease I assay and identiﬁcation
of transient genomic mutations
Genomic DNA was isolated from sgRNA/Cas9 injected speci-
mens and controls at 48 hpf. Dechorionated single embryos were
transferred to microfuge tubes and rinsed with nuclease free H2O.
Samples were incubated at 50 1C for 1–2 h in 50 ml of DNA
extraction buffer (10 mM Tris pH 8.2, 10 mM EDTA, 200 mM NaCl,
0.5% SDS, 200 mg/ml proteinase K) until completely dissolved. DNA
was extracted with 1:1 volume of phenol/chloroform/isoamyl
alcohol and precipitated with 1:10 volume 3 M sodium acetate
(pH 5.2) and EtOH at 20 1C overnight. DNA was resuspended in
10 ml TE buffer and stored at 4 1C. 2 ml of genomic DNA was used to
PCR amplify a 494 bp genomic region ﬂanking the neurod target
site (forward primer ATGACGAAGTCATACAGCGA, reverse primer
TGCACAAAAGACATCAGGTC, Fig. S12). 1 mg of PCR amplicon was
denatured and reannealed to facilitate heteroduplex formation (5-
min denaturing step at 95 1C, followed by cooling to 85 1C at
1.5 1C per second and further to 25 1C at 0.1 1C per second).
The reannealed amplicons were digested with 5U of T7 endonu-
clease I (New England Biolabs M0302S) at 37 1C for 45 min. The
reaction products were immediately resolved by electrophoresis
through a 2% agarose gel. Selected PCR products were subcloned
into pCR II-TOPO vector (Invitrogen 45-0640) according to man-
ufacturer's instructions and clones were sequenced to identify
insertion/deletion mutant alleles.
Results
Embryonic endocrine cell types display a differential sensitivity to
Neurod knockdown
To investigate the function of neurod in zebraﬁsh endocrine
pancreas development we used morpholino (MO) knockdown. We
used two different morpholinos (MOs), targeted to the 50UTR
(Neurod UTR MO) (Sarrazin et al., 2006) and to the translational
start site (Neurod ATG MO) of the neurod mRNA. Our knockdown
experiments were performed in Tg(neurod:EGFP) embryos; in these
transgenic specimens EGFP recapitulates endogenous Neurod
expression, and colocalizes with all pancreatic endocrine hormone
markers (Dalgin et al., 2011). Tg(neurod:EGFP) embryos were injected
with three different concentrations (see “Methods”) of either
Neurod UTR MO or Neurod ATG MO, and the pancreatic region
was analyzed at 30 hpf, by which stage the dorsal bud-derived
endocrine primary islet is fully formed. Control and Neurod MO
injected specimens (morphants) had normal gross morphology (Fig.
S1, and data not shown). The Neurod UTR MO not only targets the 5'
UTR of endogenous neurod mRNA but also recognizes the 50 UTR of
the Tg(neurod:EGFP) transcript. As expected, injection of Neurod UTR
MO reduced EGFP expression in Tg(neurod:EGFP) embryos, with
increasing morpholino concentration (2–8 ng) causing a reduction
in expression levels, indicative of dose-dependent knockdown
(Fig. 1A–D and false colored images Fig. S2A–D). We conﬁrmed a
concomitant decrease in endogenous Neurod protein levels in
response to increasing concentration of Neurod UTR MO by compar-
ing immunoreactivity to Neurod antibody (Kani et al., 2010) in
control and Neurod morphant embryos (Fig. 1E–H and false colored
images Fig. S2E–H). We found that Neurod immunoreactivity was
similarly depleted in response to increasing concentrations of
Neurod ATGMO (1–4 ng; not shown). Immunolabeling also revealed
heterogeneous Neurod protein expression levels in the cells of the
unmanipulated dorsal bud (Fig. 1E, inset and false colored image Fig.
S2E). These results indicate that injection of low concentrations of
Neurod MO causes partial knockdown, with a complete knockdown
of Neurod, as assessed by inability to detect protein, achieved only at
high Neurod MO concentrations. We conclude that the gradual
decrease in Tg(neurod:EGFP) expression in response to the Neurod
UTR MO provides a reliable readout of Neurod knockdown.
To analyze dorsal bud development in Neurod morphants we
examined the expression of endocrine cell markers for alpha cells
(glucagon; gcga), beta cells (insulin; insa) and delta cells (somatostatin;
sst2) by whole mount in situ hybridization at 30 hpf. In Neurod UTR
MO injected embryos, the number of gcga-expressing cells was
decreased by 96% in response to the lowest MO concentration
(2 ng; Fig. S3A–E); however the highest concentration of MO (8 ng)
was required to obtain 51% and 67% decreases in the numbers of insa
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(Fig. S3F–J) and sst2-expressing (Fig. S3K–O) cells, respectively. High
concentrations of MO were also required to obtain a signiﬁcant
decrease in epsilon cells (labeled with ghrelin; not shown). We
observed similar results in response to injection of differing concen-
trations of Neurod ATG MO (not shown). To analyze changes in the
number of endocrine cells in the context of a single islet we
examined expression of gcga and insa by double whole mount
in situ hybridization at 30 hpf. In response to the lowest MO
concentration the number of gcga-expressing cells decreased sig-
niﬁcantly but the number of insa-expressing cells did not change
(Fig. 2A and B), by contrast, a signiﬁcant decrease in the number of
insa-expressing cells was detected in response to a higher MO
concentration (Fig. 2C and D). We next performed qRT-PCR analysis
to quantify endocrine gene transcription in Neurod morphant speci-
mens relative to sibling controls. The qRT-PCR results corroborated
our in situ hybridization analysis, showing that expression of gcga
decreased 7-fold in response to the lowest MO concentration,
whereas the highest MO concentration was required to obtain 5-
and 6-fold decreases in insa and sst2 expression, respectively
(Fig. 2E). These data show that differentiation of all hormone-
expressing endocrine cell types of the dorsal bud is dependent on
Neurod, but also reveal that the glucagon-expressing alpha cells are
the most sensitive to Neurod depletion.
The homeobox transcription factor aristaless related homeobox
(Arx) is critical for alpha cell fate in mice (Collombat et al., 2003)
and in zebraﬁsh (Djiotsa et al., 2012). To investigate if the decrease
in gcga expression in Neurod morphants was due to a decrease in
arxa (the zebraﬁsh Arx homolog) expression, we analyzed the
expression of arxa transcripts in Neurod morphants. Injection of a
low concentration of Neurod MO, sufﬁcient to severely reduce the
number of gcga expressing cells, did not signiﬁcantly affect the
number of arxa-expressing cells, although at higher Neurod MO
Fig. 1. Morpholino knockdown causes progressive depletion of Neurod. Whole mount immunolabeling for GFP (green) and Neurod (red) protein. Confocal images (merged
z-stacks) of the dorsal pancreatic bud in Tg(neurod:EGFP) embryos at 30 hpf. (A, E, I) Control embryos; (E; inset) gray scale. Neurod UTR MO injected specimens (B, F, J) 2 ng/
embryo, (C, G, K) 4 ng/embryo (D, H, L) 8 ng/embryo. Scale bar¼10 mm.
Fig. 2. Quantitative analysis of Neurod morphant endocrine cell differentiation. Double in situ hybridization for glucagon (gcga, blue) and insulin (insa, red) at 30 hpf. Control
(A), Neurod UTR MO 2 ng (B), 4 ng (C) or 8 ng (D) injected specimens. Results are representative of two independent experiments and from a minimum of 20 embryos per
group. (E) Relative levels of gcga, insa and sst2 by real-time qPCR. Results are from 2 independent experiments and from 3 technical replicates and conﬁrmed by two
independent primer sets per gene of interest. All values were normalized to beta-actin levels. Primer sequences are listed in Table S1.
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concentrations severe reductions were observed (Fig. S3P–T).
These data suggest that expression of gcga depends on additional
factors beyond Arxa.
Neurod-deﬁcient endocrine precursors remain undifferentiated
The observed decrease in the number of hormone-expressing
cells in Neurod morphants could be a consequence of increased
cell death and/or decreased cell proliferation. To test these
possibilities we used the Tg(neurod:EGFP) transgenic line, in which
EGFP expression recapitulates endogenous neurod expression
(Dalgin et al., 2011). Injection of the Neurod ATG MO, which does
not block EGFP expression, allowed us to follow the fate of EGFP-
expressing cells in Neurod-deﬁcient specimens.
We detected cells undergoing cell death by immunohistochem-
istry with antibodies targeted against anti-active Caspase3 (Cas-
pase3). Three different concentrations of Neurod ATG MO were
injected into Tg(neurod:EGFP) embryos, and Caspase3-positive
EGFP-expressing cells were counted in control and morphant
specimens at 18 and 36 hpf. While we detected apoptotic cells in
the ectoderm of normal and Neurod morphant specimens, the
number of EGFP-expressing cells undergoing cell death in the
endoderm was extremely low and did not differ between control
and Neurod morphant specimens (data not shown). To investigate
whether Neurod-deﬁciency might cause ectopic cell death more
broadly we injected Neurod ATG MOs into Tg(Sox17:EGFP)
embryos, which express EGFP throughout the endoderm. Control
and morphant specimens were ﬁxed at 36 hpf and cell death
assayed. The morphology of the gut and dorsal pancreatic bud was
grossly normal in morphants when compared to controls (Fig.
S4A–D). Caspase3-labeling revealed that cell death was rare in the
endoderm, with cell death rates equivalent in control and mor-
phant specimens (Fig. S4A–D). Consistent with our ﬁndings, Flasse
et al. (2013) also failed to detect cell death in the pancreatic region
of Neurod morphant specimens. Together, these data establish that
the decrease in number of hormone expressing cells in Neurod
morphants is unlikely to be due to increased cell death.
We next tested whether the decrease in hormone expressing cells
in Neurod morphants might be due to decreased endocrine cell
proliferation. To establish proliferation rates we again used the Tg
(neurod:EGFP) line. We ﬁrst counted the total number of EGFP-
expressing cells at 18 hpf in the dorsal bud precursors of controls and
Neurod morphants. In controls the mean number of EGFP-expressing
endocrine cells was 36 (Fig. 3A and E and Fig. S5A). In Neurod
morphants injected with 1 ng or 2 ng of Neurod ATG morpholino
there was an insigniﬁcant (Po0.2 and Po0.067 respectively)
decrease in the number of EGFP-expressing cells, with a mean value
of 33 and 31 cells respectively (Figs. 3B, C, and E and S5B and C).
Specimens injected with 4 ng Neurod ATG MO showed a signiﬁcant
(21%) decrease in the number of EGFP-expressing cells (mean value
28 cells, Po0.013) (Figs. 3D and E and S5D). We next identiﬁed
proliferating cells by immunohistochemistry with antibodies against
anti-phospho-histone H3 (pH3) (images co-labeled with TO-PRO3 to
reveal the nuclei are shown in Fig. S5). Proliferation rates were low:
only 3.5% of endocrine cells were pH3-positive in control speci-
mens (Figs. 3A and F and S5A). Proliferation rates in Neurod ATG MO
injected specimens were not signiﬁcantly different (P40.1); speci-
mens injected with 1 ng, 2 ng or 4 ng of Neurod ATG MO averaged
3%, 3.7% or 2.5% pH3-positive cells respectively (Figs. 3B, C,
and F and S5B and C).
We next examined cell proliferation speciﬁcally within dorsal
bud cells. Sibling specimens from the previous experiment were
raised until 36 hpf and proliferating EGFP-expressing cells again
identiﬁed using pH3. The average number of EGFP-expressing cells
in the control dorsal bud was 48, and a similar number of EGFP-
expressing cells was found in the dorsal bud of 1 ng Neurod ATG
MO injected specimens (Figs. 3G, H, and K and S4E and F). In
contrast, we found 20% and 25% decreases in the number of EGFP-
expressing cells in the dorsal buds of 2 ng and 4 ng Neurod ATG
MO injected specimens, respectively (Po0.001) (Figs. 3I, J, and K
and S4G and H). To determine the percentage of proliferating
dorsal bud endocrine cells we counted pH3-positive EGFP-expres-
sing cells. Proliferation rates were extremely low at this stage and
did not differ signiﬁcantly between control and Neurod-deﬁcient
specimens (P40.7) (Fig. 3G–J, L). Together, these data demon-
strated that although the number of Neurod:EGFP cells decreases
in response to injection of 2 ng or 4 ng of Neurod ATG MO, the
decrease is not a consequence of reduced proliferation of endo-
crine cells. It remained possible that Neurod knockdown reduces
proliferation in endocrine precursors. To examine this possibility
we injected Neurod ATG MO into Tg(Sox17:EGFP) embryos, and
compared proliferation rates between controls and morphants of
all dorsal bud cells at 36 hpf. Neurod-deﬁciency did not cause
morphological defects and the dorsal bud was properly formed
(Figs. 3M–P and S5I–L). We counted the total number of EGFP-
expressing cells between the tip of the dorsal bud and the gut tube
(Fig. S5M); the average number of cells in control dorsal buds was
56, with similar numbers of EGFP-expressing cells present in
1 ng, 2 ng and 4 ng Neurod ATG MO injected specimens (55,
52.5 and 53, respectively). To determine the percentage of
proliferating dorsal bud cells we counted pH3-positive Sox17:EGFP
cells (Fig. S5M): 1.5% of EGFP-expressing cells were pH3-positive
in controls and this proliferation rate did not change signiﬁcantly
in Neurod ATG 1 ng, 2 ng and 4 ng MO injected specimens (1.8%,
1.9% and 1.9%, respectively). Together, our data indicate that
Neurod-deﬁciency does not cause detectable changes in rates of
cell death or proliferation within the pancreatic region. We
conclude that Neurod morphant cells are typically retained in
the developing embryos, yet remain undifferentiated. Taken
together with our analysis of hormone-expressing cell types, these
data imply that partial Neurod knockdown causes alpha cell
precursors to remain undifferentiated, whereas more extensive
Neurod knockdown blocks differentiation of all endocrine cell
types. While we do ﬁnd a signiﬁcant reduction in the number of
total Neurod:EGFP cells present in specimens lacking most or all
Neurod function, this reduction is nevertheless quite modest;
there are several possible explanations for this reduction (dis-
cussed ahead).
Endocrine cells derived from dorsal and ventral bud are equally
affected in Neurod morphants
The hormone-expressing cells of the primary islet are derived
from a combination of dorsal bud and ventral bud-derived cells,
with the two buds merging at around 52 hpf. We investigated
whether the differential sensitivity to knockdown of Neurod
observed for dorsal bud-derived endocrine cell differentiation also
holds true for ventral bud-derived endocrine cells. We again
injected Neurod UTR MO at three different concentrations, but
analyzed the fate of Tg(neurod:EGFP) cells at 72 hpf, after the dorsal
and ventral pancreatic buds have merged. Reduced EGFP expres-
sion in response to Neurod UTR MO injection conﬁrmed that the
morpholino continues to function during ventral bud-derived
endocrine cell differentiation (Fig. 4A–D, F–I, K–N, single channels
are shown in Fig. S6A–D, I–L, Q–T). Expression of hormone
markers of alpha, beta and delta cells was detected by immuno-
histochemistry, and cells were counterstained with nuclear mar-
ker TO-PRO-3 to facilitate cell counting. Consistent with our
analysis of dorsal bud-derived endocrine cell differentiation, speci-
mens injected with low levels of Neurod UTR MO (2 ng) showed
an 80% decrease in the total number of glucagon-positive cells
(Fig. 4A–E; single channels Fig. S6E–H), whereas injection of the
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highest level of Neurod UTR MO (8 ng) was required to obtain 77%
and 70% decreases in the total number of insulin (Fig. 4F–J; single
channels Fig. S6M–P) and somatostatin-expressing (Fig. 4K–O;
single channels Fig. S6U–X) cells, respectively. These data suggest
that Neurod-deﬁciency affects dorsal and ventral bud-derived
endocrine cells in a similar manner.
To conﬁrm that Neurod is required in both dorsal and ventral bud-
derived cells, we used a label-retaining method to distinguish dorsal
from ventral bud-derived cells within the primary islet at 60 hpf, after
the buds have merged. We injected one-cell stage embryos with
mRNA encoding histone (H2B-RFP) fusion protein; this protein is
retained in cells that become post-mitotic early in development, but
Fig. 3. Neurod-deﬁcient endocrine cells remain undifferentiated and have normal proliferation rate. Confocal images (merged z-stacks) of representative 18 hpf (A–D) and
36 hpf (G–H) Tg(neurod:EGFP) and 36 hpf Tg(sox17:EGFP) (M–P) embryos. Control (A, G, M), Neurod ATG MO 1 ng (B, H, N), 2 ng (C, I, O) or 4 ng (D, J, P) injected specimens.
Whole mount immunolabeling for pH3 (red, A–D, G–J, M–P). Mean (7s.d.) number of cells expressing GFP (E, K, Q) and proliferation rate is shown as mean (7 s.d.)
percentage of cells expressing pH3 and GFP (F, L, R) from 2 independent experiments and from a minimum of 10 embryos per group. *Po0.013, **Po0.001; t-test, two-tailed
distribution. NS, not signiﬁcant. Embryos are oriented anterior to the left (A–D, G–J) and to the top (M–P). Arrows indicate liver and arrowheads indicate dorsal pancreas
region. Yellow scale bar¼10 mm.
G. Dalgin, V.E. Prince / Developmental Biology 402 (2015) 81–9786
due to dilution through subsequent cell divisions is below detection
limits in cells that become post-mitotic at later stages. It was
previously reported that at 52 hpf dorsal bud-derived cells are H2B-
RFP-positive and ventral bud-derived cells are H2B-RFP-negative
(Hesselson et al., 2009; Wilﬁnger et al., 2013). Recently, experiments
using a transgenic ﬂuorescent ubiquitylation-based cell cycle indicator
(FUCCI) revealed that beta cells in the dorsal bud have a signiﬁcant,
and previously unappreciated, proliferation capacity at 36 hpf (Tsuji et
al., 2014). This new ﬁnding implies that some dorsal bud-derived cells
are likely to lack H2B-RFP labeling at 60 hpf; nevertheless any label
retaining cells observed can safely be assumed to derive from the
dorsal not the ventral bud. We therefore injected H2B-RFP mRNA
alone or together with one of three different concentrations of
Neurod ATG MO, and raised the specimens to 60 hpf. We used
immunohistochemistry to detect insulin (Fig. S7A–D, I–L) and
glucagon-expressing (Fig. S7M–P, U–X) H2B-RFP-positive and nega-
tive endocrine cells (A–H, M–T). Consistent with the ﬁndings
described above, only high concentrations of Neurod MO signiﬁcantly
decreased the number of insulin-expressing cells (Fig. S7A–D, I–L).
Importantly, Neurod knockdown decreased insulin expression in both
H2B-RFP-positive and negative cells (Fig. S7A–D), conﬁrming that
Neurod plays similar roles in dorsal and ventral bud-derived cells.
Again consistent with our previous ﬁndings, there was a dramatic
reduction of glucagon expression in specimens injected with the low
concentration of Neurod MO, and a near complete loss of glucagon
expression in response to injection of higher Neurod MO concentra-
tions (Fig. S7M–P, U–X). Both H2B-RFP positive and negative endo-
crine cells displayed this loss of glucagon expression in response to
increasing levels of Neurod MO injections (Fig. S7M–P, Q–T). Together,
these data conﬁrm that Neurod is necessary for the differentiation of
both dorsal and ventral bud-derived endocrine cells.
We next performed qRT-PCR analysis to quantify endocrine
marker gene transcription in response to Neurod knockdown. We
injected Tg(neurod:EGFP) embryos with Neurod UTR MO at three
Fig. 4. Neurod is also required for differentiation of endocrine cells from the ventral bud. Confocal images (merged z-stacks) of representative 72 hpf Tg(neurod:EGFP)
embryos. Whole mount immunolabeling for glucagon (red, A–D), insulin (red, F–I), somatostatin (red, K–N), GFP (green), with nuclear staining TO-PRO-3 (blue). Control (A, F,
K), Neurod UTR MO 2 ng (B, G, L), 4 ng (C, H, M) or 8 ng (D, I, N) injected specimens. Mean (7s.d.) number of cells expressing glucagon (E), insulin (J) and somatostatin (O)
from 5 independent experiments and from a minimum of 55 embryos per group. (P) Relative levels of gcga, insa and sst2 by real-time qPCR. Results are from 2 independent
experiments and from 3 technical replicas and conﬁrmed by two independent primer sets per gene of interest. All values were normalized to beta-actin levels. Primer
sequences are listed in Table S1. White scale bar¼10 mm.
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different concentrations and collected specimens at 72 hpf for
qRT-PCR analysis. Consistent with our immunohistochemistry
analysis (Fig. 4A–E) gcga transcript levels were decreased 5-fold
in specimens injected with the low concentration of Neurod UTR
MO (2 ng) and specimens injected with 4 ng and 8 ng of Neurod
UTR MO displayed 9- and 11-fold decreases in gcga transcript
levels, respectively (Fig. 4P). Again consistent with our immuno-
histochemistry analysis (Fig. 4F–J), injection of 2 ng Neurod UTR
MO produced only a minimal decrease in insa transcript levels
(1.8-fold; Fig. 4P), with 4 ng of Neurod UTR MO causing a 2.8-fold
reduction. Interestingly, insa transcript levels decreased only 2.3-
fold in specimens injected with the highest concentration (8 ng) of
Neurod UTR MO (Fig. 4P). These data suggest that while the
number of insulin-expressing cells decreases in response to
increasing Neurod knockdown (Fig. 4F–J), the remaining insulin-
expressing cells may try to compensate for the reduction in insulin
levels by transcribing more insa. Somatostatin-expressing cells
showed a similar response, with qRT-PCR analysis revealing that
increasing concentrations of Neurod UTR MO did not progressively
reduce sst2 transcript levels (Fig. 4P), despite reduction in the
number of somatostatin- expressing cells.
We next examined if knockdown of Neurod disrupts acinar cell
development. We injected Neurod ATG MO at three different
concentrations into Tg(ptf1a:EGFP), which marks the developing
acinar cells in zebraﬁsh exocrine pancreas (Dong et al., 2008).
Expression of hormone markers glucagon and insulin was ana-
lyzed by whole mount immunohistochemistry at 72 hpf. Injection
of a low concentration of Neurod ATG MO (1 ng) caused a near
complete loss of glucagon expression (Fig. S8A–D), and at higher
Neurod MO concentrations insulin expression was decreased
(Fig. S8E–H). However knockdown of Neurod at any concentration
did not affect the expression of ptf1a:EGFP (Fig. S8I–P), indicating
that Neurod does not have a function in acinar cell development.
Taken together, our results demonstrate that Neurod does not play
a role in acinar cell development, but that differential levels of
Neurod are required for the differentiation of individual endocrine
cell types, whether derived from dorsal or ventral bud, and that
differentiation of alpha cells is particularly sensitive to reduction
in Neurod levels.
High levels of Neurod promote differentiation of glucagon-expressing cells
Our data suggest that endocrine precursors express glucagon in
response to high levels of Neurod. To investigate whether exogenous
expression of Neurod is sufﬁcient to increase the number of glucagon-
expressing cells, we initially microinjected neurodmRNA into one-cell
stage embryos, which leads to global overexpression. However, we
found that overexpression of neurod mRNA throughout the embryo
caused gross morphological defects (not shown). We therefore
utilized an alternative approach that allowed Neurod function to be
modulated speciﬁcally within the endoderm, using cell transplanta-
tion to generate chimeric embryos in which the endoderm derives
from a donor embryo, while the other germ layers derive from a host
embryo (Stafford et al., 2006). In these experiments we used Tg
(neurod:EGFP) donor and host embryos to follow the fate of EGFP-
positive pancreatic endocrine cells (Fig. S9A, arrow). Endoderm
Fig. 5. Increased Neurod levels promote alpha cell differentiation; beta cells are less sensitive than alpha cells to Neurod knockdown. (A-R) Confocal images (merged z-
stacks) of representative 52 hpf chimeric specimens in which the entire endoderm is derived from control (A-F), Neurod morphant (G-L) or neurod mRNA injected (M-R)
donor cell transplants. Embryos are immunolabeled for EGFP (green; A, D, G, J, M, P) for glucagon (blue; B, H, N) and for insulin (blue; E, K, Q). EGFP and Rhodamine Dextran
(red) labels donor-derived cells (A, D, G, J, M, P). Merged images with all three colors are also shown (C, F, I, L, O, R). (S) Mean (± s.d.) average number of cells expressing
glucagon and EGFP-expressing endocrine cells, from a minimum of 4 chimeric embryos per group. n, Po0.002, nn, Po0.01; t-test, two-tailed distribution. (T) Mean (7 s.d.)
average number of cells expressing insulin and EGFP-expressing endocrine cells, from a minimum of 5 chimeric embryos per group. n, Po0.004; t-test, two-tailed
distribution. Scale bar¼10 µm.
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formation in host embryos was blocked using Sox32 knockdown (Fig.
S9B). By contrast, donor embryos were injected with sox32 mRNA
(together with rhodamine dextran (RD) lineage tracer), causing all
mesendodermal cells to take on an endoderm fate. To generate
chimeric embryos we transplanted RD-labeled donor endoderm into
host embryos at the blastula stage. In successful transplants the
endoderm of 52 hpf host embryos was fully reconstituted by donor
cells, showed normal morphology (red cells in Fig. S9C), and devel-
oped Tg(neurod:EGFP)-positive pancreatic cells (Fig. S9C, arrow). Using
this strategy we either knocked down or overexpressed Neurod
speciﬁcally in the donor-derived endoderm cells.
We ﬁrst used a knockdown approach to conﬁrm that Neurod
functions in the endoderm germ layer to promote endocrine
pancreas cell differentiation. We analyzed the fate of Tg(neurod:
EGFP) positive cells in transplants where the donor was either a
Neurod-positive control (Fig. 5A and D) or a Neurod-deﬁcient
morphant embryo (Fig. 5G and J). To avoid knockdown of
transgene-derived EGFP expression we used Neurod ATG MO
(2 ng). In control chimeric embryos, in which endoderm cells
expressed Neurod at endogenous levels, both glucagon- and
insulin-expressing cells differentiated (Fig. 5B, C, E, and F);
approximately 18% of the total pancreatic endocrine cells (EGFP-
expressing cells) were glucagon-positive (Fig. 5S) and 42% were
insulin-positive (Fig. 5T). By contrast, in experimental chimeric
embryos, in which the endoderm was rendered Neurod-deﬁcient
by morpholino injection, there was an almost complete failure to
differentiate glucagon-expressing cells (Fig. 5H, I, and S). The
number of insulin-expressing cells was also decreased by approxi-
mately 60% relative to controls (Fig. 5K, L, and T). These data
conﬁrm that Neurod functions directly in the endoderm germ
layer to promote endocrine cell differentiation, and, importantly,
are consistent with our whole embryo knockdown experiments,
conﬁrming that glucagon-expressing cells are more sensitive to
knockdown of Neurod than insulin-expressing cells.
We next used cell transplantation to ask if elevated Neurod levels
can promote the differentiation of glucagon-expressing cells. To test
this hypothesis we performed transplants using donor embryos that
had been microinjected with neurodmRNA (note that, at the blastula
stages when the transplants were performed, these mRNA injected
embryos remained healthy). We detected a normal number of
Neurod EGFP expressing cells in chimeric embryos in which the
endoderm overexpressed Neurod (Fig. 5M, P, S, and T). However, the
percentage of endocrine cells expressing glucagon increased signiﬁ-
cantly, from 18% to 29% (compare Fig. 5B, N, and S). By contrast, the
percentage of endocrine cells expressing insulin decreased, from 42%
to 31% (Fig. 5E, Q, and T). These data suggested that the beta cell
precursors might differentiate as alpha cells in the presence of excess
Neurod. To test this possibility we again used a transplantation
approach (Fig. S10), but for this experiment utilized Tg(mnx1:GFP)
embryos in which GFP provides a marker of beta cell precursors and
beta cells, with GFP colocalizing with insulin-expressing cells (Dalgin
et al., 2011 and Fig. S10A–C). As expected, in control chimeric
embryos Tg(mnx1:GFP)-expressing cells colabeled with insulin but
not glucagon (Fig. S10D–F). As in the previous experiment, chimeric
embryos over-expressing endodermal Neurod showed an increased
number of glucagon-expressing cells (compare Fig. S10D and G) and
a decreased number of insulin-expressing cells (compare Fig. S10E
and H). However, Tg(mnx1:GFP) did not colabel glucagon-expressing
cells (Fig. S10G and I), suggesting that excess Neurod does not cause
beta cell precursors to take on alpha cell fate. Furthermore, we
noticed that chimeric embryos overexpressing Neurod had decreased
numbers of Tg(mnx1:GFP) expressing cells (mean 1873.5 s.d.,
p¼0.08) compared to control chimeric embryos (mean 2576 s.d.),
suggesting that fewer beta cell precursors were speciﬁed in the
presence of excess Neurod. Together, these data provide strong
support for our hypothesis that differentiation of speciﬁc endocrine
cell types requires differential levels of Neurod. Speciﬁcally, glucagon-
expressing cells require high levels of Neurod to differentiate, and
elevated Neurod levels can promote differentiation of glucagon-
expressing cells.
Neurod function is required for the differentiation of IPD-derived
endocrine cells
Our experiments so far have indicated that Neurod function is
required for embryonic endocrine cell differentiation. We wished
to test whether Neurod is similarly required at larval stages for
differentiation of intra-pancreatic duct (IPD)-derived secondary
endocrine cells that will ultimately contribute to the secondary
islets. In unmanipulated specimens, larval secondary endocrine
precursor cells do not begin to develop in signiﬁcant numbers
until approximately three weeks post fertilization (Parsons et al.,
2009). However, IPD-derived endocrine precursors are Notch-
responsive cells (NRCs), and upon γ-secretase inhibition preco-
ciously produce secondary endocrine cells expressing neurod
(Fig. S11A–D). To test whether IPD-derived NRCs require Neurod
function to complete their differentiation program, we treated
control and Neurod morphant Tg(neurod:EGFP) larvae at 3 dpf with
3 mM RO4929097 (Luistro et al., 2009) (γ-secretase inhibitor here-
after) and analyzed endocrine cell differentiation at 6 dpf. We used a
low dose of Neurod MO (1 ng ATG or 2 ng UTR MO) because high
doses caused mortality at 6 dpf. At the stage of analysis, untreated
control embryos had a large primary islet composed of glucagon and
insulin-expressing cells and rare secondary Tg(neurod:EGFP)-positive
endocrine precursor cells (Fig. 6A, E, I, and J). Consistent with
previous reports (Ninov et al., 2012; Parsons et al., 2009; Wang et
al., 2011), γ-secretase inhibitor treatment caused precocious devel-
opment of large numbers of IPD-derived Tg(neurod:EGFP)-positive
endocrine precursor cells (mean 23.7671.15 s.d), many of which also
expressed glucagon or insulin, conﬁrming that these cells subse-
quently differentiated into hormone-expressing secondary endocrine
cells (Fig. 6B, F, I, and J). As EGFP expression from Tg(neurod:EGFP)
provides a convenient marker of endocrine precursors, we utilized
the Neurod ATG MO (1 ng) that targets endogenous Neurod but has
insufﬁcient sequence overlap with Tg(neurod:EGFP) to block EGFP
expression. In addition, as described above we established that
specimens injected with 1 ng of Neurod ATG MO had similar
numbers of EGFP-expressing cells compared to controls and showed
no ectopic cell death or cell proliferation defects (Figs. 3 and S4).
Comparison of γ-secretase inhibitor treated Neurod ATG morphants
with γ-secretase inhibitor treated control specimens showed that the
average cell number (mean 22.4371.58 s.d.), and the expression
levels of Tg(neurod:EGFP)-derived EGFP protein (Fig. 6B, C, F,G) and
neurod mRNA (Fig. S11B and C), were similar, indicating that Neurod
knockdown does not disrupt the initial capacity of IPD-NRCs to
produce new neurod-expressing endocrine precursors. By contrast, in
γ-secretase inhibitor treated specimens injected with Neurod UTR
MO, which does block translation of EGFP transcript, we observed a
signiﬁcant decrease in EGFP expression (but not neurod mRNA
expression Fig. S11B and D), conﬁrming that Neurod MO injection
continues to effectively block translation up to 6 dpf (Fig. 6D and H).
Importantly, the differential sensitivity of glucagon and insulin-
expressing cells to knockdown of Neurod was maintained in both
the expanding primary islet and in the precociously forming
secondary endocrine cells (Fig. 6C, D, G, and H). While Neurod-
deﬁcient specimens retained the ability to produce precocious
secondary endocrine precursors in response to Notch inhibition,
these cells largely failed to express glucagon (Fig. 6C, D, and I),
although they did express arxa (Fig. S11K and L), and only a small
number of cells expressed insulin (Fig. 6G, H, and J). These data
indicate that Neurod function is required for differentiation of IPD-
derived endocrine cells upon inhibition of Notch signaling, and
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support the hypothesis that normal endocrine pancreas cell
differentiation is dependent upon differential levels of Neurod at
both embryonic and larval stages. We conclude that Neurod plays
similar roles in the differentiation of early endocrine cells that
contribute to the primary islet and in those that develop later from
the IPD to contribute to secondary islets.
Neurod morphants show precocious endocrine precursor
development yet cannot maintain normal glucose levels
As noted above, early larvae produce only a few IPD-derived
secondary endocrine precursor cells in the absence of Notch
signaling inhibition. However, we noted that Neurod-deﬁcient
6 dpf Tg(neurod:EGFP) larvae showed a signiﬁcant increase
(approximately 4-fold) in the number of EGFP-positive secondary
endocrine precursor cells when compared to unmanipulated
controls (Fig. 7A, B, G, H, and I). While in both unmanipulated
and Neurod-deﬁcient specimens a negligible number of secondary
endocrine precursor cells have differentiated into hormone-
expressing cells at 6 dpf (Fig. 7A and F), in unmanipulated speci-
mens there is a signiﬁcant increase in the number of differentiated
endocrine cells within the primary islet between 3 and 6 dpf
(compare Fig. 4E, J with Fig. 7I). Within the 6 dpf primary islet, as
at 3 dpf, Neurod knockdown continues to cause a dramatic
reduction in the number of glucagon-expressing cells (Fig. 7E, F,
and I), as well as a signiﬁcant reduction in the number of insulin-
expressing cells (Fig. 7C, D, and I), again consistent with continu-
ing efﬁcacy of Neurod morpholino knockdown.
We hypothesized that the induction of unusually high numbers of
Tg(neurod:EGFP)-expressing endocrine precursor cells from the IPD
might be a response to functional impairment of the primary islet. To
assess islet function we analyzed free glucose levels in control and
Neurod-deﬁcient specimens as previously described (Andersson
et al., 2012; Gut et al., 2012; Jurczyk et al., 2011). The Neurod UTR
MO was injected at three different doses into Tg(neurod:EGFP)
embryos. At 3 dpf, the efﬁcacy of Neurod knockdown was conﬁrmed
by screening for a decrease in EGFP expression, and specimens were
then collected for free glucose analysis. Neurod-deﬁcient specimens
displayed higher levels of free glucose than control specimens
(Fig. 8B). Free glucose levels increased in specimens injected with
4 ng versus 2 ng of Neurod UTR MO, but we found similar free
glucose levels in specimens injected with 4 ng or 8 ng of morpholino.
These measurements were consistent with our ﬁnding that although
specimens injected with 8 ng Neurod UTR MO had fewer insulin-
expressing cells than specimens injected with 4ng Neurod UTR MO
their insulin expression levels remained similar (Fig. 4P). These
ﬁndings support our hypothesis that the spared insulin-expressing
cells might be producing more insulin to compensate for reduced
beta cell numbers. To conﬁrm a correlation between decreased beta
cell number and elevated free glucose levels we made use of Mnx1-
deﬁcient embryos, which we have previously shown fail to express
insulin and lack beta cells in the primary islet (Dalgin et al., 2011). We
predicted that Mnx1-deﬁcient specimens should have higher free
glucose levels than Neurod-deﬁcient specimens. Consistent with
expectations, 3 dpf Mnx1-deﬁcient specimens showed 5 and
2.5-fold higher free glucose levels than control and Neurod-
deﬁcient specimens, respectively (Fig. 8B). These results conﬁrm
previous ﬁndings that Mnx1-deﬁcient zebraﬁsh lack functional beta
cells, and verify that at 3 dpf the primary endocrine islet is already
functional. Together, these data strongly suggest that decreased
insulin expression and decreased beta cell numbers in Neurod
morphants (Fig. 4F–J) lead to impaired glucose homeostasis.
In the ﬁrst ﬁve days of zebraﬁsh development the yolk is the
source of nutrition, after which feeding is required for normal
development to proceed. Only those specimens injected with low
levels of Neurod MO survived to feeding stages. To determine if
Neurod function is required during feeding stages we raised
specimens injected with Neurod MO (1 ng ATG MO or 2 ng UTR
MO injected specimens) for up to 9 dpf. We conﬁrmed Neurod
knockdown by the expected decrease in EGFP, glucagon and
Fig. 6. IPD-derived secondary endocrine cells, formed in response to inhibition of Notch signaling, are sensitive to Neurod knockdown. Experimental schedule (top); Tg
(neurod:EGFP) control and Neurod morphant larvae were treated with 3 mM RO4929097 (γ-secretase inhibitor) from 3 to 6 dpf. Confocal images (merged z-stacks) of
representative 6 dpf Tg(neurod:EGFP) untreated specimen (A, E), γ-secretase inhibitor treated specimen (B, F), γ-Secretase inhibitor treated Neurod ATG morphant [1 ng] (C,
G) and γ-secretase inhibitor treated Neurod UTR morphant [2 ng] (D, H). Whole mount immunolabeling for GFP (green) and glucagon (red) (A–D) or for GFP (green) and
insulin (red) (E–H). Mean (7s.d.) number of cells expressing glucagon (I) or insulin (J) from 4 independent experiments and from a minimum of 40 and 25 larvae per group,
respectively. *Po0.0001; t-test, two-tailed distribution. Primary endocrine islet (arrow), IPD-derived endocrine cells (red line). Magniﬁcation is different in panel A than in
B–H. Scale bar¼20 μm.
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insulin expression in Neurod MO injected specimens (data not
shown). At 5 dpf, following the collection of some specimens for
free glucose assays, we commenced twice daily feeding of the
larvae (Fig. 8A). For subsequent analyses, specimens were col-
lected at 7 or 9 dpf, before the normal feeding time, and free
glucose levels were measured. Control larvae displayed an increase
in free glucose levels between 5 and 7 dpf; however, free glucose
levels dropped by 9 dpf (Fig. 8C). These data suggest that control
larvae begin to efﬁciently regulate glucose by 9 dpf. In contrast,
free glucose levels in Neurod-deﬁcient specimens continued to
Fig. 7. Neurod knockdown increases production of secondary endocrine precursor cells. Confocal images (merged z-stacks) of representative 6 dpf Tg(neurod:EGFP) Control
(A, C, E, G) and Neurod ATG morphant (B, D, F, H) specimens. Whole mount immunolabeling for insulin (C, D), glucagon (E, F) and GFP (G, H). (I) Mean (7s.d.) number of cells
expressing insulin, glucagon, GFP-positive secondary endocrine cells from 6 independent experiments and from a minimum of 20 larvae per group. *Po0.0001; t-test, two-
tailed distribution. Secondary endocrine precursor cells; arrowhead. Scale bar¼20 μm.
Fig. 8. Free glucose levels gradually increase in Neurod morphants. (A) Experimental schedule. Morpholino injected Tg(neurod:EGFP) specimens were collected for free
glucose assays at 3, 5, 7 and 9 dpf (red arrows). After 5 dpf, larvae were fed twice daily, and specimens were collected before feeding time on the appropriate days. (B) Free
glucose levels in 3 dpf Tg(neurod:EGFP) control, Neurod morphant and Mnx1 morphant specimens (MO concentrations as indicated). Mean (7s.e.m) glucose levels from
4 independent experiments. (C) Free glucose levels from 5, 7 and 9 dpf Tg(neurod:EGFP) control and Neurod MO injected specimens. As free glucose levels were similar in
Neurod ATG and UTR morpholino injected specimens these are presented together. Mean (7 s.e.m) glucose levels from 4 independent experiments. *Po0.15, **Po0.04,
***Po0.009; t-test, two-tailed distribution.
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increase after 7 dpf (Fig. 8C; ATG or UTR MO displayed similar
results). We conclude that Neurod-deﬁcient specimens fail to
maintain normal glucose levels, consistent with decreased insulin
expression and decreased beta cell numbers at feeding stages
(Fig. 8 and data not shown).
Normalization of free glucose level in Neurod morphants is not
sufﬁcient to prevent precocious endocrine precursor development
Our data suggest that decreased levels of endocrine hormone
expression in the primary islet and/or increased free glucose levels
in the larva may be the primary cause of precocious endocrine
precursor development in the IPD. To investigate the role of elevated
free glucose levels we treated control and Neurod morphant larvae
with the competitive sodium-glucose-transporter (sglt1 and 2) inhi-
bitor phlorizin. Phlorizin blocks reabsorption of glucose from the
kidney and small intestine, thereby facilitating the excretion of glucose
in the urine (Ehrenkranz et al., 2005). Tg(neurod:EGFP) control and 1 ng
Neurod ATG MO injected specimens were treated with 250 mg/ml of
phlorizin at 5.5 dpf for 16 h (Fig. 9A). Phlorizin treated control speci-
mens had similar free glucose levels to untreated controls (Fig. 9B). In
contrast, while Neurod morphants showed a signiﬁcant increase in
free glucose levels compared to controls, phlorizin treatment normal-
ized these glucose levels back to control levels (Fig. 9B). We next
analyzed IPD-derived cell differentiation, to determine if normalized
glycemic conditions would prevent precocious precursor development
in Neurod morphants treated with phlorizin. Untreated and phlorizin
treated control specimens had similar numbers of secondary endo-
crine cells (Fig. 9C–E), and the expression of glucagon and insulin in
the primary islet of phlorizin treated control specimens was normal
(Fig. 9H, I, L, M, P, and Q). In contrast, both untreated and phlorizin
treated Neurod morphant specimens had decreased glucagon and
insulin expression in the primary islet (Fig. 9J, K, N, O, R, and S) and the
number of secondary endocrine cells in these specimens increased 4
fold (Fig. 9C, F, and G). These data establish that phlorizin treatment is
able to normalize glucose levels in Neurod morphants, yet the normal
glycemic conditions are not sufﬁcient to prevent precocious precursor
development.
gRNA/Cas9 induced disruption of the endogenous neurod locus
signiﬁcantly reduces endocrine hormone expression
Recently, clustered regularly interspaced short palindromic
repeats (CRISPR) associated (Cas) has been shown to function as
a powerful mutagenesis system in many species, including zebra-
ﬁsh (Doudna and Charpentier, 2014). We used this genome editing
technology to conﬁrm the critical role of Neurod in zebraﬁsh
endocrine cell development. We selected two different neurod
target sites for single guide (sg) RNA/Cas9 binding (Fig. S12), and
found that the ﬁrst of these sites (indicated in blue, Figs. 10D and
S12) efﬁciently generated mutations.
The neurod sgRNA/Cas9 injected specimens were morphologi-
cally indistinguishable at 48 hpf from uninjected controls (Fig. 10A
and B), indicating that the reagents were not toxic. We randomly
selected two control and 11 experimental embryos injected with
neurod sgRNA/Cas9 (blue sgRNA sequence; Figs. 10D and S12) from
three independent experiments for genomic DNA extraction at
48 hpf, followed by PCR ampliﬁcation of a 494 bp region ﬂanking
the neurod sgRNA/Cas9 target sites (Fig. S12). PCR products were
then assayed with T7 endonuclease I (T7EI) to identify mismatches
diagnostic of insertion-deletion (indel) mutations. As expected the
amplicons obtained from control specimens were not cleaved by
T7EI enzyme, however, nearly all amplicons obtained from neurod
sgRNA/Cas9 injected specimens were cleaved by T7EI enzyme,
consistent with sgRNA/Cas9 injection effectively generating tran-
sient indel mutations (Fig. 10C). To determine the range of indel
mutations generated in a single embryo, we subcloned PCR
products (asterisk, Fig. 10C) into pCR II-TOPO vector and sequenced
multiple individual neurod amplicons. All the sequenced neurod
alleles (20/20) had insertions and/or deletions (Fig. 10D) conﬁrm-
ing the results of our T7EI assay. In comparison, the second sgRNA
we designed against the neurod locus (green, Fig. S12) only
produced four mutant alleles out of 44 sequenced amplicons (data
not shown).
We next performed qRT-PCR analysis to quantify gene tran-
scription in neurod sgRNA/Cas9 (blue sequence) injected speci-
mens relative to sibling controls. qRT-PCR from three independent
experiments showed that expression of neurod decreased 2.5 fold
(Fig. 10E), suggesting that sgRNA/Cas9 induced mutations caused
nonsense mediated decay (Chang et al., 2007). Consistent with this
prediction, 16/20 mutant alleles generated premature stop codons
(data not shown). Analysis of endocrine hormone markers showed
that expression of gcga, insa and sst2 decreased 2.5, 1.9 and 2-
fold respectively. To investigate possible off-target effects of the
neurod gRNA/Cas9 mRNAs we assayed expression of the liver gene
ceruloplasmin (cp) in injected specimens. qRT-PCR analysis from
the same three independent experiments showed similar levels of
cp expression in control and neurod sgRNA/Cas9 injected speci-
mens (Fig. 10E), consistent with speciﬁc gene targeting. We note
that injections with high doses of Neurod morpholino caused
more dramatic decreases in endocrine gene expression than
observed in the neurod sgRNA/Cas9 generated transient mutants,
but suggest that this likely reﬂects the incomplete and variant
nature of sgRNA/Cas9 generated mutations in the F0 generation.
Overall, our genome editing data corroborate our morpholino
knockdown experiments and conﬁrm that Neurod function is
necessary for endocrine gene transcription.
Discussion
We have shown that transcription factor Neurod plays a critical
role in zebraﬁsh endocrine pancreas cell differentiation, and that
different levels of Neurod are required for differentiation of
distinct hormone-expressing endocrine cell types. Speciﬁcally,
differentiation of alpha versus beta cells requires higher versus
lower levels of Neurod. Morpholino knockdown ﬁndings were
corroborated by two additional experimental approaches. First, we
used endoderm-speciﬁc gene modulation (both knockdown and
overexpression) to conﬁrm that different levels of Neurod function
directly in the endoderm to promote alpha versus beta cell fates.
Second, we generated sgRNA/Cas9 mediated transient mutations
in neurod to conﬁrm the requirement for Neurod in endocrine cell
differentiation. We went on to show that Neurod function is
required for the differentiation of both primary and secondary
islet cells. Our analysis further suggests that decreased endocrine
hormone expression in the primary islet of Neurod-deﬁcient
specimens triggers premature endocrine precursor production
from the IPD. However, these precociously formed endocrine
precursors do not complete their differentiation and are therefore
unable to normalize free glucose levels in larval zebraﬁsh.
The neurod transgenic reporter line Tg(neurod:EGFP) (Obholzer
et al., 2008), contributed to this study in two important ways. First,
EGFP transgene expression provided a convenient proxy for levels
of target protein expression. Second, by using an alternative
morpholino that did not target the transgene, we were able to
track the fate of Neurod-expressing cells when functional Neurod
protein was depleted. The continued expression of Tg(neurod:
EGFP) in Neurod morphants implies that Neurod function is not
required for speciﬁcation of endocrine precursors, but rather
provides a marker for these precursors, consistent with previous
reports (Dalgin et al., 2011). Consistent with this model, expression
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of Neurod throughout all endoderm does not cause ectopic Tg
(neurod:EGFP) expression, conﬁrming that Neurod function is not
sufﬁcient to specify ectopic endocrine cells.
Complete zebraﬁsh pancreas development requires the con-
tribution of cells from both the dorsal and ventral buds. We have
shown that differentiation of endocrine cells from either of these
buds requires Neurod function. In both cases, differentiation of
glucagon-positive alpha cells is more sensitive to reduced function
of Neurod than differentiation of insulin-positive beta cells. Our
analysis of Neurod-deﬁcient Tg(neurod:EGFP) and Tg(sox17:EGFP)-
expressing cells in the dorsal bud revealed that neither cell death
nor proliferation rates are detectably affected by Neurod deﬁ-
ciency. We therefore conclude that the reduced numbers of
hormone-positive cells present in Neurod-deﬁcient specimens
are primarily consequence of a block to the differentiation of
endocrine precursors: alpha cell precursors remain undifferen-
tiated in response to partial Neurod knockdown, whereas other
endocrine cell types remain undifferentiated only in response to a
more complete knockdown. In this study we used pH3 immuno-
histochemistry to reveal a snap shot of the proliferating endocrine
cells in the dorsal bud of control and Neurod morphants. Our
results are consistent with those of Hesselson et al., 2009, who
detected similar low proliferation rates using EDU and genetic
labeling of dorsal bud cells. Recently, two distinct stages of beta
cell proliferation were described at 36 hpf and 120 hpf using live
imaging with the transgenic ﬂuorescent ubiquitylation-based cell
cycle indicator (FUCCI) (Tsuji et al., 2014). Beta cell proliferation
rates detected with this advanced system are elevated in compar-
ison to those we detected with pH3 labeling; in the future it would
be interesting to use this new technology to conﬁrm endocrine cell
proliferation rates are unaffected by Neurod levels.
We also observed a modest decrease in the number of Tg(neurod:
EGFP)-expressing cells in response to injection of high doses of
Neurod-ATG-MO. Possible explanations for this include a difﬁcult to
detect brief episode of cell death, or a requirement for a low level of
Neurod function in order to maintain neurod expression (auto-
regulation). Consistent with the hypothesis of auto-regulation, neu-
rod transcript level, as detected by in situ hybridization, are reduced
in response to high doses of Neurod-UTR-MO injection (data not
shown). Ultimately, a full answer to this question will require
additional experimental approaches, including the establishment of
neurod null mutant lines, for example by using our sgRNA/Cas9
mutagenesis approach.
Alpha cell differentiation in mice and zebraﬁsh requires the
homeobox transcription factor Arx (Collombat et al., 2003; Djiotsa
et al., 2012). However, while partial knockdown of zebraﬁsh
Neurod is sufﬁcient to abrogate glucagon expression in the dorsal
bud, arxa continues to be expressed at normal levels. We similarly
observed that arxa expression is retained in IPD-derived endocrine
cells (Fig. S10IL), where again glucagon expression is abrogated.
These ﬁndings suggest either that arxa expression is insufﬁcient to
activate glucagon expression in zebraﬁsh, or alternatively, that
Fig. 9. Neurod morphants treated with sodium glucose cotransporter inhibitor retain increased production of secondary endocrine cells. (A) Experimental schedule. 1 ng of
Neurod ATG MO injected Tg(neurod:EGFP) specimens were treated with 250 μg/ml Phloridzin (Phz) at 5.5 dpf for 16 h and collected for free glucose assay. (B) Free glucose
levels in 6 dpf Tg(neurod:EGFP) untreated and Phz treated control and Neurod morphant specimens. Phz treatment normalized glucose levels in Neurod morphants. Mean
(7s.e.m) glucose levels from 4 independent experiments. (C) Mean (7s.d.) number of cells expressing GFP-positive secondary endocrine cells from 4 independent
experiments and from a minimum of 16 larvae per group. Confocal images (merged z-stacks) of representative 6 dpf Tg(neurod:EGFP) control (D, H, L, P), control treated with
phlorizin (Phz) (E, I, M, Q), Neurod ATG morphant (F, J, N, R) and Neurod ATG morphant treated with Phz (G, K, O, S). Whole mount immunolabeling for GFP (green, D–G),
glucagon (red, H–K), insulin (blue, L–O) and merged images with nuclear marker DAPI (P–S). *Po0.007, **Po0.0005; t-test, two-tailed distribution. Secondary endocrine
precursor cells; arrowhead. White scale bar¼10 μm.
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arxa is initially expressed in multiple endocrine lineages, with only
later expression becoming restricted to glucagon-expressing cells.
Detailed molecular and genetic analysis of arxa will be required to
address these possibilities in zebraﬁsh.
By using cell transplantation to generate chimeric embryos we
conﬁrmed that high levels of endodermal Neurod expression
promote differentiation of alpha cells. Chimeric embryos over-
expressing Neurod in the endoderm produce normal numbers of
Tg(neurod:EGFP) expressing endocrine precursor cells, but the
relative proportions of differentiated hormone-expressing cells
are altered. Speciﬁcally, elevated Neurod expression increases the
number of glucagon-expressing cells but decreases the number of
insulin-expressing cells. A similar role has recently been reported
for differential levels of Neurod within the developing zebraﬁsh
posterior lateral line (PLL) (Sato and Takeda, 2013). In this group of
migrating neurons there are two classes of cells, leaders and
followers, which express high and low levels of Neurod protein,
respectively. Overexpression of Neurod in a single PLL neuron
precursor is sufﬁcient to promote its differentiation into the leader
cell type (Sato and Takeda, 2013). Our immunohistochemistry has
shown that the individual cells of the dorsal endocrine pancreatic
bud similarly display heterogeneous Neurod protein levels
(Figs. 1E inset and S2E). Our observed loss of glucagon-
expressing alpha cells in response to partial depletion of Neurod
Fig. 10. Neurod sgRNA/Cas9 mediated transient mutagenesis phenocopies the endocrine cell defects found in Neurod morphants. (A) Control and (B) neurod sgRNA/Cas9
injected specimens at 48 hpf. No gross morphological defects were observed. (C) T7 endonuclease I assay (T7EI) assay. (Lane 1) marker, (lane 2) untreated and (lane 3, 4) T7EI
treated amplicons from control embryos. (Lane 5–15) Amplicons from embryos injected with neurod sgRNA/Cas9 were digested in varying ratios by T7EI enzyme. Asterisks
indicate the PCR product that was TOPO cloned and sequenced. (D) The sequence alignment of wild type (wt), insertion (18/20, red) and deletion (2/20, green) mutations
recovered from sequenced clones. Neurod sgRNA genomic target sequence (blue), protospacer adjacent motif-PAM sequence (pink). (E) Relative levels of gcga, insa, sst2,
neurod and cp by real-time qPCR. Results are from 3 independent experiments and from 2 technical replicas. All values were normalized to beta-actin levels. Primer
sequences are listed in Table S1.
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protein, and the reciprocal gain of glucagon-expressing alpha cells
from precursors in which Neurod expression has been elevated,
are consistent with a model in which glucagon expression is
dependent on high Neurod protein levels.
Differential levels of Neurod expression in speciﬁc precursor
cell populations might be achieved in a variety of ways. For
example, all endocrine cell types may transcribe similar levels of
neurod mRNA, with post-transcriptional regulation leading to
varying levels of Neurod protein in distinct cells. Such post-
transcriptional regulation could be microRNA dependent: over-
expression of the murine beta cell microRNA (miR)-30a-5p direc-
tly suppresses expression of NeuroD to induce beta cell dysfunc-
tion (Kim et al., 2013). An alternative possibility is that activation
of different enhancers controlling neurod transcription could allow
differential Neurod levels to arise in distinct endocrine cell types.
Our analysis of phylogenetically conserved sequences has revealed
multiple putative enhancer regions that might regulate Neurod
transcription (not shown). In preliminary experiments we have
identiﬁed a regulatory region that is ﬁrst activated in beta-cells
(GD unpublished, to be discussed elsewhere). In the future, a
thorough analysis will be necessary to address how differential
levels of Neurod are activated in the endocrine precursors.
Notch-responsive cells (NRCs) in the duct are a source of
endocrine precursor cells in both mouse and zebraﬁsh (Apelqvist
et al., 1999; Jensen et al., 2000; Kopinke et al., 2011; Ninov et al.,
2012; Parsons et al., 2009; Wang et al., 2011). Our results reveal
that cell fate decisions are determined at least in part by differ-
ential levels of Neurod expression after Notch signaling is inhibited
in the newly formed endocrine precursors. Notch mediated sup-
pression of cellular differentiation occurs through activation of
Hes1, which in turn inhibits expression of bHLH proteins (Davis
and Turner, 2001; Jarriault et al., 1998). Both neurog3 and neurod
encode bHLH proteins and are thus potential Notch targets in the
developing pancreas. Consistent with this prediction we have
shown that Notch signaling inhibition increases neurod expression
(Fig. S11A–D). Similarly, zebraﬁsh mind bomb mutants, which have
disrupted Delta-mediated Notch signaling, show strongly elevated
neurod expression (Zecchin et al., 2007). The human NEUROG3
gene has multiple HES1 binding sites and is directly repressed by
HES1 (Lee et al., 2001). As the zebraﬁsh neurog3 mutant does not
have endocrine pancreatic defects (Flasse et al., 2013), it will be
especially important to address in future studies whether zebraﬁsh
neurod is directly regulated by Hes1 in the IPD.
Our free glucose analysis indicated that Neurod morphants are
unable to maintain normal glucose levels. This may indicate that
the reduced number of beta cells that differentiate in Neurod
morphants is insufﬁcient to produce sufﬁcient insulin, or alter-
natively, that those beta cells that do form lose functionality as
they mature. Consistent with the latter hypothesis, mouse Neu-
roD1 is required to maintain functional maturity of beta cells (Gu
et al., 2010). We have also found that in Neurod-deﬁcient larvae
there is a robust increase in progenitor maturation from the IPD. It
has recently been shown that beta cell differentiation from the
zebraﬁsh larval IPD also increases in response to high nutrient
conditions, with mTOR signaling implicated in the activation of
IPD-Notch responsive cells (Ninov et al., 2012). Glucose metabo-
lism within beta cells has been proposed as a signal to induce beta
cell replication in mammals (Dadon et al., 2012), and in vitro
experiments using cultured rodent pancreatic rudiments have
shown that glucose can control beta cell differentiation by reg-
ulating expression of NeuroD (Guillemain et al., 2007). While these
previous reports suggest that elevated glucose levels might sti-
mulate progenitor maturation from the IPD, our experiments using
phlorizin to normalize glucose levels do not support this hypoth-
esis: normalizing glucose levels in Neurod morphants does not
prevent precocious endocrine precursor production from the IPD.
In these experiments, in which we manipulated Neurod levels at
larval zebraﬁsh stages, our partial knockdown likely recapitulates
a hypomorphic mutant condition. Thus we propose that reduced
primary islet hormone levels and/or sustained defects caused by
reduced levels of Neurod, promote new endocrine precursor
production from the IPD at stages when beta cells begin to
function in metabolism.
In conclusion, our results have revealed that activation of
differential levels of Neurod plays an important role in the determi-
nation of endocrine cell fate choice. Flasse et al. (2013) recently
reported that Neurod and another Notch-regulated bHLH protein,
Ascl1b, play complementary roles in zebraﬁsh endocrine cell devel-
opment. This previous work (Flasse et al., 2013) used a relatively low
dose of Neurod MO (3 ng), which we would expect to cause loss of
only glucagon expression from the dorsal bud. However, when
Neurod and Ascl1b genes were simultaneously knocked down a
complete loss of dorsal bud-derived endocrine cell types resulted.
Such ﬁndings indicate that multiple factors are involved in endocrine
cell differentiation, with Neurod functioning as one component of a
broader gene network comprising both cell-intrinsic factors and cell-
extrinsic signals that ultimately establish speciﬁc endocrine fates. We
previously showed that Mnx1 is required for differentiation of beta
cell fate. Thus, we predict that while low levels of Neurod together
with Mnx1 are required for beta cell differentiation, high levels of
Neurod together with as yet unidentiﬁed factors might be required
for alpha cell differentiation. Similarly, Sussel and colleagues have
suggested that the combined functions of transcription factors
Nkx2.2 and NeuroD1 regulate the fate of multiple endocrine cell
types in mice (Mastracci et al., 2013). Our results show a role for
Neurod in both primary and secondary endocrine cell differentiation,
with Neurod functioning in an equivalent fashion in both instances.
Equivalent mechanisms do not always act in primary and secondary
cells, as recently shown for retinoic acid (RA) signaling, which
promotes primary endocrine cell development from the dorsal
pancreatic bud yet inhibits secondary endocrine cell development
from the IPD (Rovira et al., 2011). Recently, Matsuda and colleagues
additionally showed that RA activity controls IPD cell commitment
and maturation (Matsuda et al., 2013). However, our data reveal that
subsequent to endocrine cell commitment Neurod activity is
required to differentiate distinct endocrine cell types. A more
complete understanding of the molecular processes that underlie
both primary and secondary endocrine cell differentiation will be
helpful in the establishment of in vitro protocols for the differentia-
tion of endocrine cells for use in cell-based therapies.
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